<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="519">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870688</url>
  </required_header>
  <id_info>
    <org_study_id>VPA 044/K</org_study_id>
    <nct_id>NCT00870688</nct_id>
  </id_info>
  <brief_title>Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening</brief_title>
  <official_title>Non Interventional Trial of Valproate Sustained Release Minitablets Once Daily in the Evening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Desitin Arzneimittel GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Desitin Arzneimittel GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Valproate is the first line therapy in primary generalized seizures. The applied drug
      contains sodium valproate in sustained release minitablets. As a multiple unit dosage form
      these can be easily swallowed and taken independent from meals.

      A simple dosage scheme like valproate sustained release minitablets once daily in the
      evening should improve the compliance and likely the seizure situation of the patients. The
      data of this non interventional trial were directly extracted from the physician's
      electronic patient database. The observational period was 7 weeks compared to a
      retrospective period 7 weeks before start of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change in Number of Seizures After Conversion To Valproate Retard Minitablets Once Daily</measure>
    <time_frame>7 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seizures Within 7 Weeks</measure>
    <time_frame>7 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Data About Efficacy, Safety and Compliance</measure>
    <time_frame>7 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">82</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>epilepsy patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium valproate</intervention_name>
    <description>valproate sustained release minitablets, once daily.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Orfiril (R) long</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        community sample outpatients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age of 12 years and above

          -  epilepsy patients

          -  indication to initiation / conversion to valproate sustained release minitablets once
             daily

        Exclusion Criteria:

          -  contraindication to valproate use

          -  no indication for conversion to valproate sustained release minitablets once daily
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2009</verification_date>
  <lastchanged_date>May 19, 2009</lastchanged_date>
  <firstreceived_date>January 9, 2009</firstreceived_date>
  <firstreceived_results_date>January 9, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Karin Lohmueller</name_title>
    <organization>Desitin Arzneimittel GmbH</organization>
  </responsible_party>
  <keyword>valproate</keyword>
  <keyword>epilepsy</keyword>
  <keyword>compliance</keyword>
  <keyword>sustained released minitablet</keyword>
  <keyword>Orfiril long</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In total 82 patients were included in this trial. The patients were naive or changed from another antiepileptic or valproate preparation to valproate sustained release minitablets once daily in the evening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sodium Valproate</title>
          <description>Epilepsy patients receive valproate sustained release minitablets, once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death, Unrelated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Granules in the Stools</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sodium Valproate</title>
          <description>Epilepsy patients receive valproate sustained release minitablets, once daily.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="82"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="61"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="45.9" spread="23"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="43"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Number of Seizures After Conversion To Valproate Retard Minitablets Once Daily</title>
        <time_frame>7 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Data About Efficacy, Safety and Compliance</title>
        <time_frame>7 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seizures Within 7 Weeks</title>
        <time_frame>7 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Sodium Valproate</title>
            <description>Epilepsy patients receive valproate sustained release minitablets, once daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="82"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seizures Within 7 Weeks</title>
            <units>seizures</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.6" spread="2.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lohmueller</name_or_title>
      <organization>Desitin</organization>
      <phone>0049(0)40-59101 ext 373</phone>
      <email>lohmueller@desitin.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
